Clinicopathologic characteristics, treatment, and outcomes of post-transplant Lymphoproliferative disorders: A single-institution experience using 2017 WHO diagnostic criteria

Rebecca King, Arushi Khurana, Raphael Mwangi, Angelo Fama, Kay M. Ristow, Matthew J. Maurer, William R Macon, Stephen M. Ansell, N. Nora Bennani, Yogish C. Kudva, Randall C. Walker, Kymberly D Watt, Thomas Schwab, Sudhir Kushwaha, James R. Cerhan, Thomas M. Habermann

Research output: Contribution to journalArticlepeer-review

Abstract

The World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (WHO 2017) included updated criteria for diagnosis and classification of post-transplant lymphoproliferative disorders (PTLDs). This study evaluated the clinicopathologic spectrum using WHO 2017 criteria and adult PTLD patients’ outcomes over 30 years between 1987 and 2017 at Mayo Clinic (Rochester, MN). Patients were retrospectively reviewed for clinical features, outcomes, and diagnostic pathology material and classified based on WHO 2017 criteria. A total of 227 patients were diagnosed with PTLD, with a median time from transplant to PTLD of 45 months. PTLD occurred >1 year after transplant in 149 (66%) patients. Monomorphic PTLD was the most common subtype (173, 76%), with diffuse large B cell lymphoma as the commonest morphology (n = 137). Epstein-Barr virus was positive in 61% of total cases and 90% of PTLD that developed within 1 year from transplant. The median event-free survival (EFS) and overall survival for the entire cohort were 21 months (95% confidence interval [CI]: 9–35) and 82 months (95% CI: 39–115), respectively. The EFS or overall survival was not impacted by Epstein-Barr virus status but differed based on WHO subtypes and year of diagnosis. Management changed over time with increased use of rituximab or chemotherapy + immunosuppression reduction as initial therapy. When compared to the matched general population and de novo diffuse large B cell lymphoma, patients not achieving EFS 24 status (no progression/treatment or death within 24 mo of diagnosis) had a worse standardized mortality ratio 16.75 (95% CI: 13.91–20) versus SMR 1.72 (95% CI: 1.26–2.28) in those who achieved EFS24. Cause of death was mostly attributed to non-lymphoma–related causes in those achieving EFS 24.

Original languageEnglish (US)
Article numbere640
JournalHemaSphere
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Clinicopathologic characteristics, treatment, and outcomes of post-transplant Lymphoproliferative disorders: A single-institution experience using 2017 WHO diagnostic criteria'. Together they form a unique fingerprint.

Cite this